PriceTargets.com logo

Hookipa Pharma - HOOK Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $44.00
  • Forecasted Upside: 1,517.65%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.72 As of 11/20/2024 01:00 AM ET
▼ -0.07 (-2.51%)

This chart shows the closing price for HOOK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hookipa Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HOOK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HOOK

Analyst Price Target is $44.00
▲ +1,517.65% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Hookipa Pharma in the last 3 months. The average price target is $44.00, with a high forecast of $60.00 and a low forecast of $24.00. The average price target represents a 1,517.65% upside from the last price of $2.72.

This chart shows the closing price for HOOK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Hookipa Pharma. This rating has held steady since November 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$50.00 ➝ $48.00
8/9/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.00
7/26/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$50.00 ➝ $23.00
6/5/2024HC WainwrightBoost TargetBuy ➝ Buy$50.00 ➝ $60.00
5/21/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$50.00
4/26/2024HC WainwrightLower TargetBuy ➝ Buy$65.00 ➝ $50.00
3/25/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$50.00
3/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$65.00
1/30/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$60.00 ➝ $50.00
9/27/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$70.00
9/6/2023Truist FinancialReiterated RatingBuy ➝ Buy$40.00
8/11/2023HC WainwrightLower TargetBuy ➝ Buy$80.00 ➝ $65.00
6/30/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$70.00
3/20/2023Truist FinancialLower Target$110.00 ➝ $40.00
3/16/2023HC WainwrightReiterated RatingBuy$80.00
12/2/2022Bank of AmericaDowngradeBuy ➝ Underperform
11/15/2022Royal Bank of CanadaLower TargetOutperform$80.00 ➝ $70.00
8/23/2022Truist FinancialLower TargetBuy$160.00 ➝ $110.00
8/12/2022HC WainwrightReiterated RatingBuy
8/11/2022Leerink PartnersLower TargetOutperform$40.00 ➝ $30.00
3/25/2022HC WainwrightReiterated RatingBuy$80.00
3/25/2022Royal Bank of CanadaLower TargetOutperform$110.00 ➝ $90.00
2/17/2022HC WainwrightLower TargetBuy$150.00 ➝ $80.00
2/16/2022Truist FinancialLower Target$230.00 ➝ $160.00
2/16/2022Leerink PartnersBoost TargetOutperform$30.00 ➝ $40.00
2/8/2022Leerink PartnersReiterated RatingOutperform
12/22/2021UBS GroupDowngradeBuy ➝ Neutral
11/12/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$60.00
11/11/2021HC WainwrightLower TargetBuy$210.00 ➝ $150.00
11/10/2021Leerink PartnersLower TargetOutperform$280.00 ➝ $100.00
11/10/2021Royal Bank of CanadaLower TargetOutperform$240.00 ➝ $170.00
11/10/2021JMP SecuritiesLower TargetOutperform$250.00 ➝ $110.00
9/19/2021Leerink PartnersReiterated RatingBuy
8/18/2021Morgan StanleyLower TargetOverweight$190.00 ➝ $180.00
6/27/2021Leerink PartnersReiterated RatingBuy
6/4/2021JMP SecuritiesReiterated RatingBuy$250.00
5/19/2021Leerink PartnersReiterated RatingBuy$280.00
5/13/2021HC WainwrightBoost TargetBuy$160.00 ➝ $210.00
4/8/2021Morgan StanleyInitiated CoverageOverweight$190.00
3/21/2021Leerink PartnersReiterated RatingBuy$280.00
11/30/2020JMP SecuritiesBoost TargetOutperform$190.00 ➝ $250.00
11/3/2020Truist FinancialInitiated CoverageBuy$210.00
10/26/2020JMP SecuritiesInitiated CoverageMarket Outperform$190.00
10/19/2020HC WainwrightReiterated RatingBuy$160.00
8/16/2020Royal Bank of CanadaReiterated RatingBuy$180.00
6/17/2020HC WainwrightReiterated RatingBuy$150.00
1/10/2020HC WainwrightReiterated RatingBuy$150.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 2 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Hookipa Pharma logo
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Read More

Today's Range

Now: $2.72
Low: $2.62
High: $2.81

50 Day Range

MA: $4.00
Low: $2.79
High: $5.28

52 Week Range

Now: $2.72
Low: $2.62
High: $11.30

Volume

56,569 shs

Average Volume

57,400 shs

Market Capitalization

$32.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Hookipa Pharma?

The following Wall Street research analysts have issued reports on Hookipa Pharma in the last twelve months: HC Wainwright, JMP Securities, and Royal Bank of Canada.
View the latest analyst ratings for HOOK.

What is the current price target for Hookipa Pharma?

0 Wall Street analysts have set twelve-month price targets for Hookipa Pharma in the last year. Their average twelve-month price target is $44.00, suggesting a possible upside of 1,517.6%. HC Wainwright has the highest price target set, predicting HOOK will reach $60.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $24.00 for Hookipa Pharma in the next year.
View the latest price targets for HOOK.

What is the current consensus analyst rating for Hookipa Pharma?

Hookipa Pharma currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HOOK will outperform the market and that investors should add to their positions of Hookipa Pharma.
View the latest ratings for HOOK.

What other companies compete with Hookipa Pharma?

Other companies that are similar to Hookipa Pharma include Neon Therapeutics, Skye Bioscience, Telomir Pharmaceuticals, Context Therapeutics and Ventyx Biosciences. Learn More about companies similar to Hookipa Pharma.

How do I contact Hookipa Pharma's investor relations team?

Hookipa Pharma's physical mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The company's listed phone number is 431-890-6360 and its investor relations email address is [email protected]. The official website for Hookipa Pharma is www.hookipapharma.com. Learn More about contacing Hookipa Pharma investor relations.